April 16, 2007 15:54 ET

AtheroGenics to Report First Quarter 2007 Financial Results on April 26, 2007

ATLANTA, GA--(CCNMatthews - April 16, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its first quarter 2007 financial results on Thursday, April 26, 2007, before the U.S. financial markets open.

Conference Call and Webcast Information

Company officials will provide a company update and discuss first quarter results via conference call and webcast on Thursday, April 26, 2007, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-612-689-8031 (international). The call can also be accessed via the webcast through the AtheroGenics website at Participants may also access a replay of the conference call approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international). The call will be archived until May 3, 2007.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. AtheroGenics' lead compound, AGI-1067, has completed a Phase III clinical trial as an oral therapy for the treatment of atherosclerosis. AtheroGenics and AstraZeneca have a worldwide collaboration covering the development and commercialization of AGI-1067. In addition to AGI-1067, the Company has a clinical-stage development program studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas.AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit

Contact Information